Department of Epidemiology, University of North Carolina, Chapel Hill, USA.
Lancet Infect Dis. 2011 Jan;11(1):57-64. doi: 10.1016/S1473-3099(10)70214-0.
After the launch of the National Malaria Control Programme in 1953, the number of malaria cases reported in India fell to an all-time low of 0·1 million in 1965. However, the initial success could not be maintained and a resurgence of malaria began in the late 1960s. Resistance of Plasmodium falciparum to chloroquine was first reported in 1973 and increases in antimalarial resistance, along with rapid urbanisation and labour migration, complicated the challenge that India's large geographical area and population size already pose for malaria control. Although several institutions have done drug-resistance monitoring in India, a complete analysis of countrywide data across institutions does not exist. We did a systematic review of P falciparum malaria drug-efficacy studies in India to summarise drug-resistance data and describe changes over the past 30 years to inform future policy. Continued use of chloroquine for treatment of P falciparum malaria in India will likely be ineffective. Resistance to sulfa-pyrimethamine should be closely monitored to protect the effectiveness of treatment with artesunate plus sulfadoxine-pyrimethamine, which is the new first-line treatment for P falciparum malaria. Strategies to reduce the emergence and spread of future drug resistance need to be proactive and supported by intensive monitoring.
1953 年启动国家疟疾控制规划后,印度报告的疟疾病例数量在 1965 年降至历史最低点,为 0.1 百万人。然而,最初的成功未能持续,疟疾在 20 世纪 60 年代末再次抬头。1973 年首次报告恶性疟原虫对氯喹产生耐药性,抗疟药物耐药性的增加,加上城市化和劳动力迁移的快速发展,使印度庞大的地域面积和人口规模给疟疾控制带来的挑战更加复杂。尽管有几个机构在印度进行了耐药性监测,但各机构之间并没有对全国范围的数据进行全面分析。我们对印度的恶性疟原虫疟疾药物疗效研究进行了系统评价,以总结耐药性数据,并描述过去 30 年来的变化,为未来的政策提供信息。在印度继续使用氯喹治疗恶性疟原虫疟疾可能无效。应密切监测磺胺多辛-乙胺嘧啶的耐药性,以保护青蒿琥酯加磺胺多辛-乙胺嘧啶的治疗效果,后者是恶性疟原虫疟疾的新一线治疗药物。减少未来药物耐药性出现和传播的策略需要积极主动,并得到强化监测的支持。